JPRN-UMIN000006543Completed未知
Efficacy and safety of Fondaparinux for prevention of venous thromboembolism (VTE) after abdominal surgery - Efficacy and safety of Fondaparinux for prevention of venous thromboembolism (VTE) after abdominal surgery
Kansai Medical University Hirakata hospital0 sites100 target enrollmentStarted: December 31, 2013Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 100
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18years-old to 90years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1.Patient who meet contraindication or precaution in package insert of anticoagulants such as Fondaparinux, UFH, LMWH, and Danaparoid 2.Patient who have experience of lower limb orthopedic surgery, abdominal surgery, cardiovascular surgery within 3 month of enrollment 3.Patient who receive contra indicated concomitant drug within 1 week after Fondaparinux administration. 4.VTE patient diagnosed before surgery 5.Patient whose D-dimer above 1 micro gram before surgery 6.Patient who have history of arterial thromboembolism 7.Drug addiction or alcohol abuse. 8.Patient who scheduled other surgery during the study 9.Pregnant women or women who have possibility of pregnancy. 10.Patient who judged inadequate to join the study by the doctor in charge.
Investigators
Similar Trials
Active, not recruiting
Not Applicable
Safety and efficacy of fondaparinux 1.5 mg in the prevention of venous thromboembolism in medical patients with severe renal insufficiency - NDHospitalized medical patients with moderate to severe renal insufficiency and indication to the use of pharmacological antithrombotic prophylaxisEUCTR2008-005234-79-ITDIPARTIMENTO DI MEDICINA CLINICA - UNIVERSITA` DEGLI STUDI DELL`INSUBRIA
Terminated
Not Applicable
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.Renal FailureNCT00256100Melbourne Health20
Completed
Phase 2
Evaluation of Fondaparinux in Patients With a Heart Rhythm Disturbance Who Undergo Restoration of Normal Heart RhythmFibrillation, AtrialNCT00911300GlaxoSmithKline349
Terminated
Phase 3
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU PatientsVenous ThromboembolismNCT00493896Eastern Virginia Medical School27
Completed
Phase 3
Phase III study of efficacy of fondaparinux on the prevention of post-operative venous thromboembolism in patients undergoing with laparoscopic colorectal cancer surgery.Colorectal cancersJPRN-UMIN000008435Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group300